PCM
AGIO icon

Peregrine Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Peregrine Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-162,905
Closed -$6.54M – 295
2025
Q3 		$6.54M Buy
+162,905
New +$6.13M 0.2% 146
2020
Q4 		– Sell
-164,315
Closed -$5.75M – 338
2020
Q3 		$5.75M Sell
164,315
-15,655
-9% -$686K 0.15% 214
2020
Q2 		$9.63M Buy
+179,970
New +$8.33M 0.27% 132

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Peregrine Capital Management's AGIO Position: Q4 2025 in Review

Peregrine Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2025, closing a stake of 162,905 shares — an estimated $6.54M sold.

Peregrine Capital Management first reported a position in AGIO in Q2 2020 and held it in 3 quarters. The position peaked at $9.63M in Q2 2020. 238 funds tracked by Wall St. Rank hold AGIO as of Q4 2025.

  • Peregrine Capital Management reported no remaining Agios Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Peregrine Capital Management sold 162,905 Agios Pharmaceuticals shares in Q4 2025, an estimated $6.54M.
  • Peregrine Capital Management first reported a position in Agios Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Peregrine Capital Management's Agios Pharmaceuticals position peaked at $9.63M in Q2 2020.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2025.

Based on Peregrine Capital Management's 13F filing for Q4 2025, filed 28 Jan 2026.